Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2018-07-27 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
MIV-711 osteoarthritis phase IIa extension study outcomes show continuing positive effect on joint structure
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing positive top-line outcomes from a Phase IIa extension study (MIV-711-202) regarding joint structure effects in osteoarthritis patients. It details clinical results, quotes the CEO, and mentions ongoing discussions with potential partners. This type of announcement, focusing on clinical trial results and business updates, is characteristic of an Earnings Release (ER) or a general press release related to operational/clinical progress. Since it is not a full annual report (10-K), a comprehensive interim report (IR), or a formal transcript (CT), and it specifically details the *release* of study outcomes, it fits best as an Earnings Release (ER) which often includes key operational/clinical highlights, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure not covered elsewhere. Given the content is a direct announcement of study results and business outlook, ER is the most appropriate fit among the specific options, as it functions as a key periodic update, even if not strictly quarterly earnings. It is not a Report Publication Announcement (RPA) because it contains the substantive results, not just a notice that a report is available.
2018-07-27 English
Resultaten från fas IIa-fortsättningsstudien med MIV-711 för artros visar fortsatt positiv påverkan på ledstrukturer
Earnings Release Classification · 96% confidence The document is a press release from Medivir AB, dated July 27, 2018, announcing positive top-line results from a Phase IIa continuation study (MIV-711-202) for MIV-711 in osteoarthritis. It details clinical trial outcomes, safety profiles, and future plans (presenting data at a conference, seeking partners). This type of announcement, focusing on the initial release of key clinical trial results, aligns best with an Earnings Release (ER) if it were quarterly results, but since it is a specific clinical trial update, it functions as a primary announcement of new scientific/development progress. However, given the provided definitions, this is not a standard 10-K, AR, or IR. It is a specific announcement of results, which often falls under a general 'Regulatory Filing' (RNS) or, if it were a summary of financial performance, an ER. Since it is a detailed announcement of clinical trial results and market potential, it is most closely related to an Earnings Release (ER) in function (announcing period performance/progress) or a general Regulatory Filing (RNS). Given the context of a pharmaceutical company announcing trial results, this is a significant corporate event announcement. It is not a transcript (CT), a presentation (IP), or a formal report (10-K/IR). It is a direct announcement of results, making 'ER' (Earnings Release, used here broadly for key periodic performance/progress announcements) or 'RNS' (Regulatory Filing) the closest fits. Since it is a specific, non-financial period result announcement, RNS is the most appropriate fallback for a significant, non-standard filing, although ER captures the 'release of results' nature. I will classify it as RNS as it is a specific regulatory announcement outside the standard financial reporting cycle. FY 2017
2018-07-27 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Medivir AB covering the period January to June 2018. It contains comprehensive financial summaries (Net sales, EBITDA, earnings per share, cash flow) for both the quarter and the six-month period, alongside detailed management commentary on clinical projects and R&D. It is a substantive financial report rather than a mere announcement or certification. H1 2018
2018-07-25 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is titled 'MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2018'. It contains comprehensive financial summaries for the quarter and the six-month period, including net turnover, EBITDA, earnings per share, and cash flow. It also includes a CEO's message, detailed R&D project updates, and project tables. As it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2018
2018-07-25 English
Medivir announces positive top-line results from the MIV-711 osteoarthritis phase IIa extension study
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing positive top-line results from a clinical study (MIV-711 osteoarthritis phase IIa extension study). It details study endpoints, patient numbers, safety profiles, and quotes the Chief Medical Officer. The concluding statement, "This is information that Medivir AB is obliged to make public pursuant to the EU Market Abuse Regulation," strongly suggests this is a mandatory disclosure of material, non-public information. This type of announcement, focusing on clinical trial results and regulatory compliance, is typically classified as an Earnings Release (ER) if it's a periodic update, or more generally, a Regulatory Filing (RNS) if it's a specific, non-periodic material event disclosure required by market abuse rules that doesn't fit other categories like ER or DIV. Since it is a specific announcement of clinical trial success rather than a comprehensive financial report (10-K, IR) or a general earnings summary (ER), and it is a direct regulatory disclosure, RNS is the most appropriate general regulatory fallback. However, given the content is a direct announcement of key operational/clinical results, it functions similarly to an Earnings Release (ER) which often includes operational highlights, but ER is usually reserved for quarterly/periodical financial results. Since this is a specific, material, non-periodic operational update mandated by regulation, RNS (Regulatory Filings/General Announcement) is the best fit among the provided options for a non-standard, material disclosure.
2018-06-28 English
Medivir presenterar positiva topline resultat från fas IIa-fortsättningsstudien med MIV-711 för artros
Earnings Release Classification · 95% confidence The document is a press release from Medivir AB announcing positive top-line results from a Phase IIa extension study (MIV-711-202) for their drug MIV-711 for osteoarthritis. It details clinical outcomes, safety profiles, and quotes the Chief Medical Officer. This type of announcement, focusing on the initial release of key periodic financial/clinical results, aligns best with the 'Earnings Release' (ER) definition, even though it pertains to clinical trial data rather than standard quarterly revenue/profit figures. It is a direct announcement of results, not a comprehensive report (10-K, IR) or a presentation (IP). The final paragraph explicitly states the information is being made public under EU market abuse regulation, confirming it is a formal regulatory announcement of results. FY 2017
2018-06-28 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.